Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combinatorial drug screening identifies synergistic co-targeting of Bruton’s tyrosine kinase and the proteasome in mantle cell lymphoma

27 Aug 2013

Abstract excerpt

We have performed a focused combinatorial screen of targeted drugs combined with ibrutinib in mantle cell lymphoma (MCL) cells, and identified the proteasome inhibitor carfilzomib as a targeted agent that could be used with ibrutinib to provide improved clinical responses. Other targeted agents that displayed cytotoxic benefit in our screen also were independent of the B-cell receptor (BCR) pathway, whereas...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Lymphocytic Leukemia Research
Share to Lymphoma Diagnosis and Treatment
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23979520
DOI: 10.1038/leu.2013.249

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combinatorial drug screening identifies synergistic co-targeting of Bruton’s tyrosine kinase and the proteasome in mantle cell lymphomaPMID 23979520Read ↗

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cellsSemantic proximity Read ↗

Novel treatment for mantle cell lymphoma - impact of BTK inhibitors and beyond.Semantic proximity Read ↗

BTK Inhibitors and BTK Degraders for the Treatment of Mantle Cell Lymphoma - Current Status and PerspectivesSemantic proximity Read ↗

Novel agents for mantle cell lymphoma: molecular rational and clinical data.Semantic proximity Read ↗

Inhibition of BIRC5 and MCL1 as a potential treatment strategy to overcome drug resistance in Mantle Cell LymphomaSemantic proximity Read ↗

The B cell receptor signaling pathway in mantle cell lymphomaSemantic proximity Read ↗

Targeting CDK4/6 in mantle cell lymphomaSemantic proximity Read ↗

Targeting Bruton's Tyrosine Kinase in CLL.Semantic proximity Read ↗

Rocbrutinib in Covalent BTK Inhibitor Exposed Relapsed or Refractory Mantle Cell Lymphoma: a Phase 2, Open-label, Multicenter, Single-arm StudySemantic proximity Read ↗

Transcriptomic profiling in canine B-cell lymphoma supports a synergistic effect of BTK and PI3K inhibitorsSemantic proximity Read ↗

Ibrutinib treatment of CLL: the cancer fights back.Semantic proximity Read ↗

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.